Document is current
Any future updates will be listed below
-
Authors
Calafat, Margalida https://orcid.org/0000-0003-2335-3792
Mañosa, Míriam https://orcid.org/0000-0002-9051-2581
Cañete, Fiorella https://orcid.org/0000-0003-4589-9497
Domènech, Eugeni https://orcid.org/0000-0002-2315-7196
- License Information
-
More Information
Article History
Accepted: 27 December 2020
First Online: 13 January 2021
Declarations
:
: No sources of funding were used to support the writing of this review.
: MC has served as a speaker or has received research or education funding or advisory fees from Takeda, Janssen, Faes Farma, and MSD; FC has served as a speaker or has received research or education funding or advisory fees from Takeda, Janssen, MSD, and Ferring; MM has served as a speaker or has received research or education funding or advisory fees from FAES, Ferring MSD, AbbVie, Takeda, and Janssen; ED has served as a speaker and has received research and educational funding and advisory fees from MSD, AbbVie, Takeda, Celltrion, Samsung Bioepis, Kern Pharma, Pfizer, Janssen, Celgene, Adacyte Therapeutics, Otsuka Pharmaceuticals, Ferring, Shire Pharmaceuticals, Tillots, Thermofisher, Grifols, Gilead, Roche, and Gebro.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MC and ED drafted the manuscript. MM and FC critically reviewed the manuscript and added valuable contributions. All the authors approved the final version of the manuscript.
